---
title: "Dosing | Kisqali®"
description: "Explore Kisqali dosing in ABC: once-daily dosing with AI or fulvestrant, 600 mg starting dose, with or without food, at the same time each day."
canonical_url: "https://www.kisqali.com/advanced-breast-cancer/monitoring-and-dosing/dosing"
meta:
  "og:description": "Explore Kisqali dosing in ABC: once-daily dosing with AI or fulvestrant, 600 mg starting dose, with or without food, at the same time each day."
  "og:title": Dosing
---

## **Dosing**

### **KISQALI provides convenient dosing with either an AI or fulvestrant. \***<sup>(1)</sup>

**KISQALI has a once-daily dosing regimen: **<sup>(1)</sup>

- The recommended starting dose is 600 mg (3 x 200 mg tablets)
- KISQALI can be taken with or without food. Patients should be encouraged to take their dose at approximately the same time each day, preferably in the morning

![28-day dosing schedule illustrating KISQALI 600mg (3 tablets/day) taken for 21 consecutive days followed by 7 days off, combined with continuous AI or Fulvestrant. Fulvestrant is administered on Days 1 and 15 of Cycle 1, then monthly. Diagram shows daily tablet intake and injection timeline.](https://www.kisqali.com/img/advanced-breast-cancer/mobile/kisqali-dosing-schedule-28day-ai-fulvestrant.svg)

\* KISQALI is prescribed in combination with an AI or fulvestrant in pre-, peri- and postmenopausal women. In pre- or perimenopausal women, KISQALI should be prescribed in combination with AI or fulvestrant alongside an LHRH agonist. KISQALI should not be co-administered with tamoxifen.  
  
 Please refer to the respective Summary of Product Characteristics for more information on dosing. <sup>(1)</sup>  
<sup>†</sup> Continue treatment as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs. <sup>(1)</sup>

## Sitemap

See the full [sitemap](/sitemap.md) for all pages.